PA
ORGO icon

PharVision Advisers’s Organogenesis Holdings ORGO Stock Holding History

PharVision Advisers’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.4K Sell
35,622
-27,567
-44% -$95.5K 0.86% 60
2025
Q4 		$327K Buy
63,189
+26,488
+72% +$128K 0.17% 228
2025
Q3 		$155K Buy
+36,701
New +$171K 0.09% 567

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PharVision Advisers's ORGO Position: Q1 2026 in Review

PharVision Advisers reduced its Organogenesis Holdings (ORGO) stake by 44% in Q1 2026, selling an estimated $95.5K and leaving 35,622 shares worth $84.4K. The position accounts for 0.86% of the portfolio, ranked #60.

PharVision Advisers first reported a position in ORGO in Q3 2025 and has held it in 3 quarters since. The position peaked at $327K in Q4 2025. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • PharVision Advisers held 35,622 shares of Organogenesis Holdings worth $84.4K as of Q1 2026.
  • PharVision Advisers sold 27,567 Organogenesis Holdings shares in Q1 2026, an estimated $95.5K.
  • Organogenesis Holdings made up 0.86% of PharVision Advisers's portfolio in Q1 2026, its #60 holding.
  • PharVision Advisers first reported a position in Organogenesis Holdings in Q3 2025 and has held it in 3 quarters since.
  • PharVision Advisers's Organogenesis Holdings position peaked at $327K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.